Mega Genomics (HKSE:06667) ROCE % : 2.78% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mega Genomics's annualized ROCE % for the quarter that ended in Dec. 2023 was 2.78%.

Mega Genomics ROCE % Historical Data

The historical data trend for Mega Genomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics ROCE % Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

27.47

57.31

23.16

-2.97

5.65

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			15.43	9.90	-16.77	8.59	2.78

Mega Genomics ROCE % Calculation

Mega Genomics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	40.799	/	( ( (788.064 - 90.729)	+	(871.241 - 125.053) )	/ 2 )
	=	40.799	/	( (697.335	+	746.188)	/ 2 )
	=	40.799	/	721.7615
	=	5.65 %

Mega Genomics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	20.436	/	( ( (804.121 - 77.698)	+	(871.241 - 125.053) )	/ 2 )
	=	20.436	/	( ( 726.423	+	746.188 )	/ 2 )
	=	20.436	/	736.3055
	=	2.78 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Mega Genomics (HKSE:06667) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mega Genomics ROCE % Related Terms

Thank you for viewing the detailed overview of Mega Genomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics (HKSE:06667) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.

Executives

Guo Meiling	2101 Beneficial owner
Lin Lin	2101 Beneficial owner
Yu Rong	2501 Other
Infinite Galaxy Health Limited	2101 Beneficial owner
Mei Nian Investment Limited	2101 Beneficial owner
Kastle Limited	2501 Other
Mega Marvelous Limited	2501 Other
Yurong Technology Limited	2101 Beneficial owner
Niu Zhencai	2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines